Published May 2015 | Version v1
Journal article Metadata-only

Double blind randomized prospective trial of bethanechol in the prevention of radiation-induced salivary gland dysfunction in head and neck cancer patients

Creators

  • 1. Stomatology Department, A.C. Camargo Cancer Center, São Paulo (Brazil)
  • 2. Nuclear Medicine Department, A.C. Camargo Cancer Center, São Paulo (Brazil)
  • 3. Head and Neck Department, A.C. Camargo Cancer Center, São Paulo (Brazil)
  • 4. Radiotherapy Department, A.C. Camargo Cancer Center, São Paulo (Brazil)
  • 5. Head and Neck Department, Hospital do Câncer de Barretos, São Paulo (Brazil)

Description

This study assessed the prophylactic bethanechol use to prevent salivary gland dysfunction during radiotherapy. A total of 97 head and neck cancer patients were allocated into two groups: Bethanechol or Placebo. Bethanechol group presented significantly improve of salivary parameters. Bethanechol was effective in decreasing the salivary gland damage

Availability note (English)

Available from http://dx.doi.org/10.1016/j.radonc.2015.03.017

Additional details

Identifiers

DOI
10.1016/j.radonc.2015.03.017;
PII
S0167-8140(15)00156-5;

Publishing Information

Journal Title
Radiotherapy and Oncology
Journal Volume
115
Journal Issue
2
Journal Page Range
p. 253-256
ISSN
0167-8140
CODEN
RAONDT

INIS

Country of Publication
Ireland
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
47026516
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CARCINOMAS; HEAD; NECK; PATIENTS; RADIOTHERAPY; SALIVARY GLANDS; SCINTISCANNING
Descriptors DEC
BODY; COUNTING TECHNIQUES; DIAGNOSTIC TECHNIQUES; DISEASES; GLANDS; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; ORGANS; RADIOISOTOPE SCANNING; RADIOLOGY; THERAPY

Optional Information

Copyright
Copyright (c) 2015 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.